Something important is missing in the ACC/AHA cholesterol treatment guidelines

Journal of the American Pharmacists Association

Volumn 55, Issue 3, 2015, Pages 324-329

  McKenney, James M ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b National Clinical Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

AMERICAN; CARDIOLOGIST; CONTINUING EDUCATION; CORONARY ARTERY ATHEROSCLEROSIS; DYSLIPIDEMIA; HUMAN; MEDICAL EXPERT; MEDICAL SOCIETY; NOTE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STANDARDS;

CHOLESTEROL; GUIDELINE ADHERENCE; GUIDELINES AS TOPIC; HUMANS;

EID: 84929760336     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2015.15008     Document Type: Note

References (20)

1. Stone NJ, Robinson JG, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889-2934.
2. Ginsberg HN. The 2013 ACC/AHA guidelines on the treatment of blood cholesterol. Questions, questions, questions. Cir Res. 2014;114:761-764.
3. Grundy SM. Statin for all? Am J Cardiol. 2014;114:1443-1446.
4. Pencina MJ, Navar-Boggan AM, D'Agostino RB, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370:1422-1431.
5. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013;382:1762-1765.
6. Nissen SE. Prevention guidelines: bad process, bad outcome. JAMA 2014;174:1972-1973.
7. Smith SC, Grundy SM. State-of-the-art review. 2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. J Am Coll Cardiol. 2014;64:601-612.
8. Anderson TJ, Gregoire J, Hegele RA, et al. Viewpoint. Are the ACC/AHA guidelines on the treatment of blood cholesterol a game changer? A perspective from the Canadian Cardiovascular Society Dyslipidemia Panel. Can J Cardiol. 2014;30:377-380.
9. Ray KK, Kastelein JJP, Boekholdt SM, et al. The ACC/AHA 2013 guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014:35:960-968.
10. Expert Panel on Dyslipidemia. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia: executive summary. Atherosclerosis. 2014;232:410-413.
11. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
12. The expert panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med. 1988;148:36-69.
13. The expert panel. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
15. Carroll MD, Kit BK, Lacher DA, et al. Trends in lipids and lipoproteins in US adults, 1988-2010. JAMA. 2012;308:1545-1554.
16. Kaufman HW, Blatt AJ, Huang X, et al. Blood Cholesterol Trends 2001-2011 in the United States: analysis of 105 Million Patient Records. Plos One. 2013;8:e63416.
17. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
18. Grundy SM, Cleeman JI, Merz CN, et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
19. Graham R, Mancher M, Wolman DM, et al., eds. Clinical Practice Guidelines We Can Trust. Washington, DC: Institute of Medicine/National Academies Press; 2011.
20. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 - executive summary. J Clin Lipidol. 2014;8:473-488.